Gene therapy treatment gives Baby Kiama a lifeline, saving him from world’s most expensive drug that he needed to slow down a ...

A majority of people are calling for the urgent inclusion of screening in the infant “heel prick” test for a genetic disease that causes severe muscle degeneration to allow for early diagnosis and ...

Lumenis announced the launch of OptiLift, a dynamic muscle stimulation technology intended to improve lower eyelid laxity, ...

Treatment with Spinraza (nusinersen) can help stabilize or improve motor function in adults with SMA, according to a new ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration FDA has accepted its Biologics License Application BLA for ...

Activating a protein called potassium channel Kv2.1 may help improve motor function in SMA, making it a potential SMA ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

For patients who feel their Botox wears off quickly, Dr. Zalka often suggests increasing the dosage slightly. “Injecting a ...